logo
logo

Deepcure Closes $40M Series A Funding Led By Morningside Ventures

Nov 08, 2021over 3 years ago

Amount Raised

$40 Million

Round Type

series a

Boston

Description

DeepCure, a leader in developing novel, small molecule therapeutics using the world’s largest AI drug discovery engine, announced today the closing of a $40 million Series A financing round led by Morningside Ventures, with participation from existing investors TLV Partners, Sapir Venture Partners, and Benon Group Ltd. The Company has raised a total of $47 million in financing since its inception.

Company Information

Company

Deep Cure

Location

Boston, Massachusetts, United States

About

Deepcure was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists, and biologists. Using an end-to-end drug discovery platform and automated robotic wet lab, the Company is developing a novel pipeline of precision small molecules across many different therapeutic indications. DeepCure’s founding team includes some of the industry’s preeminent researchers and technologists. Our vision is to use AI-driven discovery to create better small molecules therapeutics and faster cures for every disease-relevant protein target. DeepCure is based in Boston, MA. For more information, visit http://www.deepcure.ai/.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech